Julio Mantero
About
In The Last Decade
Julio Mantero
13 papers receiving 557 citations
Hit Papers
Peers
Comparison fields: 5 of 75
- Molecular Biology 242
- Neurology 138
- Pathology and Forensic Medicine 133
- Pulmonary and Respiratory Medicine 99
- Immunology 94
Countries citing papers authored by Julio Mantero
This map shows the geographic impact of Julio Mantero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julio Mantero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julio Mantero more than expected).
Fields of papers citing papers by Julio Mantero
This network shows the impact of papers produced by Julio Mantero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julio Mantero. The network helps show where Julio Mantero may publish in the future.
Co-authorship network of co-authors of Julio Mantero
This figure shows the co-authorship network connecting the top 25 collaborators of Julio Mantero. A scholar is included among the top collaborators of Julio Mantero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julio Mantero. Julio Mantero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Single-cell multiregion dissection of Alzheimer’s disease breakdown → | 83 |
| 2 | 68 | |
| 3 | 30 | |
| 4 | 25 | |
| 5 | Single-cell dissection of the human brain vasculature breakdown → | 173 |
| 6 | Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. | 30 |
| 7 | 15 | |
| 8 | 17 | |
| 9 | 38 | |
| 10 | 38 | |
| 11 | 27 | |
| 12 | 14 | |
| 13 | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.